HomeCompareECGS vs PFE

ECGS vs PFE: Dividend Comparison 2026

ECGS yields 2000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ECGS wins by $9939315158.48M in total portfolio value
10 years
ECGS
ECGS
● Live price
2000.00%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9939315158.53M
Annual income
$9,049,252,674,478,578.00
Full ECGS calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — ECGS vs PFE

📍 ECGS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodECGSPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ECGS + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ECGS pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ECGS
Annual income on $10K today (after 15% tax)
$170,000.00/yr
After 10yr DRIP, annual income (after tax)
$7,691,864,773,306,791.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, ECGS beats the other by $7,691,864,773,284,471.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ECGS + PFE for your $10,000?

ECGS: 50%PFE: 50%
100% PFE50/50100% ECGS
Portfolio after 10yr
$4969657579.29M
Annual income
$4,524,626,337,252,418.00/yr
Blended yield
91.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ECGS
No analyst data
Altman Z
-45.2
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ECGS buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricECGSPFE
Forward yield2000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$9939315158.53M$49.6K
Annual income after 10y$9,049,252,674,478,578.00$26,258.71
Total dividends collected$9876141646.27M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ECGS vs PFE ($10,000, DRIP)

YearECGS PortfolioECGS Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$210,700$200,000.00$9,153$693.39+$201.5KECGS
2$4,163,767$3,938,317.76$8,593$849.25+$4.16MECGS
3$77,191,133$72,735,902.82$8,336$1,066.78+$77.18MECGS
4$1,342,813,676$1,260,219,163.76$8,437$1,384.80+$1342.81MECGS
5$21,925,333,121$20,488,522,486.99$9,013$1,875.40+$21925.32MECGS
6$336,109,296,351$312,649,189,912.21$10,306$2,680.72+$336109.29MECGS
7$4,838,913,266,619$4,479,276,319,522.88$12,820$4,101.38+$4838913.25MECGS
8$65,446,276,951,058$60,268,639,755,775.59$17,673$6,826.70+$65446276.93MECGS
9$831,834,097,245,644$761,806,580,908,011.90$27,543$12,591.86+$831834097.22MECGS
10$9,939,315,158,531,418$9,049,252,674,478,578.00$49,560$26,258.71+$9939315158.48MECGS

ECGS vs PFE: Complete Analysis 2026

ECGSStock

Falcon Technologies, Inc. provides various design-build infrastructure services. The company offers telecommunications and data infrastructure services, which include communications infrastructure services to commercial, government, and other business enterprises. It also provides engineering services, program management, construction, installation and maintenance services, premise wiring services, tower and radio infrastructure services, and technology implementation and integration services, as well as a portfolio of infrastructure engineering and construction services. In addition, it offers design/build, installation, and maintenance services for electrical systems in factories, offices, healthcare facilities, government bases, and installations; and cell-phone relay towers, as well as sells electrical equipment, such as light fixtures, switchgear/panels, and fire alarm and control systems. Further, the company undertakes fire protection contracts in Northern California to provides layout and installation of various types of fire sprinkler systems, including wet and dry pipe, pre-action, in-rack, and fire pump systems in various commercial and industrial applications in new corporate headquarters, shopping centers, multi-tenant buildings, hospitals, nursing facilities, schools, and churches. Additionally, it offers emergency fire protection services with a fleet of approximately 25 service trucks. The company serves commercial builders/developers, government contractors, federal and state governments, education sector, and city/county. Falcon Technologies, Inc. is based in Rancho Cordova, California.

Full ECGS Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ECGS vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ECGS vs SCHDECGS vs JEPIECGS vs OECGS vs KOECGS vs MAINECGS vs JNJECGS vs MRKECGS vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.